Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present application is related to a novel coronavirus S protein double-region subunit nano-vaccine based on a bacterial complex. In the present invention, a receptor binding domain (RBD) and a fusion peptide (FP) of a virus are used together as double antigens, and are connected to a bacterial complex (such as PF_Ferritin or Lumazine Synthase (LS)) to form a fusion protein, so as to achieve antigen multimerization; and then expression is performed by using a eukaryotic cell expression system, and a 24-mer nano-antigen or a 60-mer nano-antigen can be formed by means of self-assembly action. The solution can overcome the defect of insufficient immunogenicity of an RBD monomer. The obtained vaccine can significantly increase the level of a neutralizing antibody against a virus in a host, and the resulting antibody has the capability of strongly blocking a virus from invading a target cell.

The present application is related to a novel coronavirus S protein double-region subunit nano-vaccine based on a bacterial complex. In the present invention, a receptor binding domain (RBD) and a fusion peptide (FP) of a virus are used together as double antigens, and are connected to a bacterial complex (such as PF_Ferritin or Lumazine Synthase (LS)) to form a fusion protein, so as to achieve antigen multimerization; and then expression is performed by using a eukaryotic cell expression system, and a 24-mer nano-antigen or a 60-mer nano-antigen can be formed by means of self-assembly action. The solution can overcome the defect of insufficient immunogenicity of an RBD monomer. The obtained vaccine can significantly increase the level of a neutralizing antibody against a virus in a host, and the resulting antibody has the capability of strongly blocking a virus from invading a target cell.

The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.

The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.

The invention relates to the use of melanin, complexed with a peptide, in particular containing epitopes for use as an immunostimulatory composition, wherein the peptide that has been modified as to increase nucleophilicity.

The invention relates to the use of melanin, complexed with a peptide, in particular containing epitopes for use as an immunostimulatory composition, wherein the peptide that has been modified as to increase nucleophilicity.

The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of sequences described in the specification.

The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of sequences described in the specification.

The present disclosure is directed to a system for displaying antigens. This system includes an outer membrane vesicle comprising a lipid bilayer and a synthetic antigen receptor comprising an outer membrane scaffold protein fused to a biotin-binding protein, where the outer membrane scaffold protein is incorporated in the lipid bilayer and the biotin-binding protein is displayed outside the outer membrane vesicle. Also disclosed are therapeutic compositions, nucleic acid constructs, expression vectors, and methods of eliciting an immune response in a subject.